Skip to main content

Department

Toxicology

Preferred Sample Type

Diltiazem

Suitable Specimen Types

  • Serum
  • EDTA Plasma
  • Li Hep Plasma
A minimum of 500 µl of plasma/serum is required.

Specimen Transport

First class post

Sample Processing in Laboratory

Place sample in toxicology rack.

Sample Preparation

None required

Turnaround Time

3 days.

Sample Stability

Keep refrigerated. 4 degrees.

Diltiazem

General Information

Diltiazem is a calcium channel blocker used in the treatment of angina pectoris, hypertension and superventricular arrhythmias since 1973. Adult oral doses are usually within a range of 60 – 420 mg daily and are administered in 1 – 2 portions.

The most common adverse reactions for diltiazem include weakness, edema, dizziness, nausea, vomiting and rash. In overdosage, bradycadia, hypotension, cardiac failure and death may occur.

Patient Preparation

For TDM, sample should be taken prior to dose.

If toxicity is suspected, take sample at earliest opportunity

Notes

Diltiazem measured by HPLC-DAD.

Please note this assay is not currently UKAS accredited 

Reference Range

Therapeutic use of diltiazem is typically associated with concentrations between 0.05 to 0.4 mg/L. Toxicity is generally associated with concentrations > 0.8 mg/L.  (Clarke's Analysis of Drugs & Poisons, Third Edition).

Specifications

  • EQA Scheme?: Yes
  • EQA Status: LGC QUARTZ, LGC CLIN TOX